Atazanavir: Difference between revisions
Jump to navigation
Jump to search
| Line 25: | Line 25: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Atazanavir (ATV) is an azapeptide HIV-1 protease inhibitor (PI). The compound selectively inhibits the virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells, thus preventing formation of mature virions.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = REYATAZ (ATAZANAVIR SULFATE) CAPSULE, GELATIN COATED [E.R. SQUIBB & SONS, L.L.C.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=165cff62-b284-4a27-a65d-9ec8a5bfcdd8#nlm34089-3 | publisher = | date = | accessdate}}</ref> | |||
==References== | ==References== | ||
Revision as of 16:32, 7 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]
Overview
Category
US Brand Names
REYATAZ®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Dosage and Administration | How Supplied
Mechanism of Action
Atazanavir (ATV) is an azapeptide HIV-1 protease inhibitor (PI). The compound selectively inhibits the virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells, thus preventing formation of mature virions.[1]
References
- ↑ "REYATAZ (ATAZANAVIR SULFATE) CAPSULE, GELATIN COATED [E.R. SQUIBB & SONS, L.L.C.]". Text " accessdate" ignored (help)